IGFBP7 Human, His
Insulin Like Growth Factor Binding Protein-7Human Recombinant, His Tag
Cat. No.
BT17208
Source
Escherichia Coli.
Synonyms
Insulin-like growth factor-binding protein 7, IBP-7, IGF-binding protein 7, IGFBP-7, IGFBP-rP1, MAC25 protein, PGI2-stimulating factor, Prostacyclin-stimulating factor, Tumor-derived adhesion factor, TAF, IGFBP7, MAC25, PSF, AGM, FSTL2, RAMSVPS, IGFBP-7v, IGFBPRP1.
Appearance
Sterile Filtered clear solution.
Purity
Greater than 85% as determined by SDS-PAGE.
Usage
THE BioTeks products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs 
In Stock 
Description
IGFBP7 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 279 amino acids (27-282 a.a.) and having a molecular mass of 28.8kDa.
IGFBP7 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
Product Specs
Introduction
Insulin-like Growth Factor-Binding Protein 7 (IGFBP7), a member of the IGFBP family, is characterized by its cysteine-rich nature and conserved cysteine residues. These proteins share common structural features, including an IGFBP domain, a Kazal-like domain, and an Ig-like C2-type domain. IGFBP7 is widely expressed in various normal human tissues. However, its expression is frequently downregulated in cancer cell lines originating from the prostate, breast, colon, and lung. Functionally, IGFBP7 plays a crucial role in skeletal myogenesis. It binds to IGF, inhibiting IGF-induced differentiation of skeletal myoblasts without affecting IGF-induced proliferation. Additionally, IGFBP7 demonstrates growth-suppressive effects on prostate and breast cancer cell lines. This suppression occurs through an IGF-independent mechanism, leading to cell cycle arrest in the G1 phase and increased apoptosis.
Description
Recombinant human IGFBP7, expressed in E. coli, is a single, non-glycosylated polypeptide chain. It consists of 279 amino acids (residues 27-282) and has a molecular weight of 28.8 kDa. The protein includes a 23-amino acid His-tag at the N-terminus and is purified using proprietary chromatographic techniques.
Physical Appearance
The product appears as a clear, sterile-filtered solution.
Formulation
The IGFBP7 protein solution is provided at a concentration of 0.25 mg/ml. It is formulated in a buffer containing 20 mM Tris-HCl (pH 8.0), 0.2 M NaCl, 50% glycerol, 2 mM DTT, and 1 mM EDTA.
Stability
For short-term storage (up to 2-4 weeks), the product should be stored at 4°C. For long-term storage, it is recommended to store the product frozen at -20°C. The addition of a carrier protein (0.1% HSA or BSA) is recommended for long-term storage. Avoid repeated freeze-thaw cycles to maintain protein stability.
Purity
The purity of IGFBP7 is determined to be greater than 85% using SDS-PAGE analysis.
Synonyms
Insulin-like growth factor-binding protein 7, IBP-7, IGF-binding protein 7, IGFBP-7, IGFBP-rP1, MAC25 protein, PGI2-stimulating factor, Prostacyclin-stimulating factor, Tumor-derived adhesion factor, TAF, IGFBP7, MAC25, PSF, AGM, FSTL2, RAMSVPS, IGFBP-7v, IGFBPRP1.
Source
Escherichia Coli.
Amino Acid Sequence
MGSSHHHHHH SSGLVPRGSH MGSSSSDTCG PCEPASCPPL PPLGCLLGET RDACGCCPMC ARGEGEPCGG GGAGRGYCAP GMECVKSRKR RKGKAGAAAG GPGVSGVCVC KSRYPVCGSD GTTYPSGCQL RAASQRAESR GEKAITQVSK GTCEQGPSIV TPPKDIWNVT GAQVYLSCEV IGIPTPVLIW NKVKRGHYGV QRTELLPGDR DNLAIQTRGG PEKHEVTGWV LVSPLSKEDA GEYECHASNS QGQASASAKI TVVDALHEIP VKKGEGAEL.
Product Science Overview
Structure and Function
IGFBP7 binds to insulin-like growth factor I (IGF-I) and insulin-like growth factor II (IGF-II) with relatively low affinity compared to other members of the IGFBP family . Despite this lower affinity, IGFBP7 has several important functions:
- Regulation of IGF Availability: By binding to IGFs, IGFBP7 regulates their availability in tissues and body fluids, thereby influencing various physiological processes .
- Stimulation of Prostacyclin Production: IGFBP7 stimulates the production of prostacyclin, a potent vasodilator and inhibitor of platelet aggregation .
- Cell Adhesion: IGFBP7 promotes cell adhesion, which is essential for maintaining tissue structure and function .
Biological Significance
IGFBP7 is involved in several biological processes, including:
- Cell Growth and Differentiation: IGFBP7 plays a role in the growth, differentiation, and proliferation of mammalian cells .
- Tumor Suppression: IGFBP7 has been implicated in the suppression of tumor growth and progression. It is involved in the regulation of cell growth and apoptosis, making it a potential target for cancer therapy .
- Angiogenesis: IGFBP7 is involved in the regulation of angiogenesis, the process of new blood vessel formation, which is crucial for tissue repair and regeneration .
Recombinant IGFBP7 with His Tag
The recombinant form of IGFBP7, tagged with a polyhistidine (His) sequence, is commonly used in research and therapeutic applications. The His tag facilitates the purification and detection of the protein, making it easier to study its structure and function in various experimental settings.
Clinical Implications
IGFBP7 has been associated with several diseases and conditions, including:
- Diabetic Angiopathy: IGFBP7 is involved in the pathogenesis of diabetic angiopathy, a condition characterized by damage to blood vessels due to diabetes .
- Retinal Arterial Macroaneurysm: A variant of IGFBP7 has been linked to retinal arterial macroaneurysm, a condition that affects the blood vessels in the retina .
Quick Inquiry
Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
